ConductScience.org, home

Paper38947237

The significance of finerenone as a novel therapeutic option in diabetic kidney disease: a scoping review with emphasis on cardiorenal outcomes of the finerenone phase 3 trials.

Arici M and 9 others. Front Med (Lausanne), 2024. Cited by 12 papers, by iCite.

Cite this record

ConductScience Library. The significance of finerenone as a novel therapeutic option in diabetic kidney disease: a scoping review with emphasis on cardiorenal outcomes of the finerenone phase 3 trials. Papers, record 38947237. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38947237

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The significance of finerenone as a novel therapeutic option in diabetic kidney disease: a scoping review with emphasis on cardiorenal outcomes of the finerenone phase 3 trials.
PubMed
Journal
Front Med (Lausanne)
PubMed
Year
2024
PubMed
Publication types
Journal Article, Scoping Review
PubMed
Citations, by iCite
12
iCite
Relative citation ratio, by iCite
2.17, provisional
iCite
Revised in PubMed
2025-01-30
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Arici MMustafa
2Altun BBulent
3Araz MMustafa
4Atmaca AAysegul
5Demir TTevfik
6Ecder TTevfik
7Guz GGalip
8Gogas Yavuz DDilek
9Yildiz AAlaattin
10Yilmaz TTemel

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References111

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
123067652KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update.Am J Kidney Dis2012https://conductscience.org/library/papers/23067652PubMed
216445274Hyperkalemia.Am Fam Physician2006https://conductscience.org/library/papers/16445274PubMed
333720773Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options.Circulation2021https://conductscience.org/library/papers/33720773PubMed
435784710
Efficacy and Safety of Non-Steroidal Mineralocorticoid Receptor Antagonists in Patients With Chronic Kidney Disease and Type 2 Diabetes: A Systematic Review Incorporating an Indirect Comparisons Meta-Analysis.
Front Pharmacol2022https://conductscience.org/library/papers/35784710PubMed
534811750Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease.Br J Pharmacol2022https://conductscience.org/library/papers/34811750PubMed
626325557Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.JAMA2015https://conductscience.org/library/papers/26325557PubMed
735061867Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study.Diabetes Care2022https://conductscience.org/library/papers/35061867PubMed
820650892A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule.J Biol Chem2010https://conductscience.org/library/papers/20650892PubMed
929276100Revisiting RAAS blockade in CKD with newer potassium-binding drugs.Kidney Int2018https://conductscience.org/library/papers/29276100PubMed
1034514191Mineralocorticoid Receptor Antagonism in Chronic Kidney Disease.Kidney Int Rep2021https://conductscience.org/library/papers/34514191PubMed
1136742404Finerenone in type 2 diabetes and renal outcomes: A random-effects model meta-analysis.Front Endocrinol (Lausanne)2023https://conductscience.org/library/papers/36742404PubMed
1233688855Outcome trends in people with heart failure, type 2 diabetes mellitus and chronic kidney disease in the UK over twenty years.EClinicalMedicine2021https://conductscience.org/library/papers/33688855PubMed
1335023547Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.Eur Heart J2022https://conductscience.org/library/papers/35023547PubMed
1429548765The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling.Kidney Int2018https://conductscience.org/library/papers/29548765PubMed
1529554312Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis.Eur Heart J2018https://conductscience.org/library/papers/29554312PubMed
1632970396Dapagliflozin in Patients with Chronic Kidney Disease.N Engl J Med2020https://conductscience.org/library/papers/32970396PubMed
1736335326
Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease.
Cardiovasc Diabetol2022https://conductscience.org/library/papers/36335326PubMed
1836303247
Network meta-analysis on the efficacy and safety of finerenone versus SGLT2 inhibitors on reducing new-onset of atrial fibrillation in patients with type 2 diabetes mellitus and chronic kidney disease.
Diabetol Metab Syndr2022https://conductscience.org/library/papers/36303247PubMed
1927431783Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone (BAY 94-8862) in Individuals With Renal Impairment.Clin Pharmacol Drug Dev2016https://conductscience.org/library/papers/27431783PubMed
2032802705Significance of SGLT2 inhibitors: lessons from renal clinical outcomes in patients with type 2 diabetes and basic researches.Diabetol Int2020https://conductscience.org/library/papers/32802705PubMed

See all 111 referencesDownload CSV of references

Cited by13

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 12 citations.

PMIDTitleJournalYearIn PapersSource
42943236Safety and Efficacy of Finerenone in Diabetic Kidney Disease: A Single-Center Retrospective Real-World Comparative Study of Dosing and Clinical Decision-Making in Taiwan.Pharmaceuticals (Basel)2026https://conductscience.org/library/papers/42943236PubMed
42193565Does Psychological Flexibility Correlate with Mystical Experiences: A Machine Learning Approach Including State of Surrender, Near-Death Experiences, and Psilocybin Consumption.Behav Sci (Basel)2026https://conductscience.org/library/papers/42193565PubMed
42192808Effects of a Single Sub-Anesthetic Dose of Ketamine in Tobacco Use Disorder: An Active-Placebo, Randomized Crossover Study.Brain Sci2026https://conductscience.org/library/papers/42192808PubMed
42171960Finerenone in Cardiorenal Disease: A Narrative Review of Molecular Mechanisms, Clinical Evidence, and Emerging Therapeutic Roles.Cardiovasc Drugs Ther2026https://conductscience.org/library/papers/42171960PubMed
41877062A systematic review and meta-analysis of mesenchymal stem cell therapy in diabetic nephropathy and lupus nephritis or proteinuric nephropathy.BMC Nephrol2026https://conductscience.org/library/papers/41877062PubMed
41824283Comorbidity-Driven Inflammation in HFpEF: Immune Profiling and Therapeutic Targets.Curr Heart Fail Rep2026https://conductscience.org/library/papers/41824283PubMed
41790294Comparative efficacy of mineralocorticoid receptor antagonists in prevention of adverse cardiovascular events: a network meta-analysis.Heart Fail Rev2026https://conductscience.org/library/papers/41790294PubMed
41765963Dissecting the role of mineralocorticoid receptors in binge-like alcohol drinking in mice: Finerenone as a potential pharmacotherapy.Psychopharmacology (Berl)2026https://conductscience.org/library/papers/41765963PubMed
41369803Chronic kidney disease following left ventricular assist device implantation: contemporary insights and future perspectives.Heart Fail Rev2025https://conductscience.org/library/papers/41369803PubMed
41301427Regulation of Klotho Production by Mineralocorticoid Receptor Signaling in Renal Cell Lines.Biomolecules2025https://conductscience.org/library/papers/41301427PubMed
40534883Immune-mediated renal injury in diabetic kidney disease: from mechanisms to therapy.Front Immunol2025https://conductscience.org/library/papers/40534883PubMed
40021271Finerenone Efficacy in Patients with Chronic Kidney Disease, Type 2 Diabetes, and Anemia in FIDELITY.JACC Adv2025https://conductscience.org/library/papers/40021271PubMed
39911073Cardiovascular Efficacy and Safety of Finerenone: A Meta-Analysis of Randomized Controlled Trials.Clin Cardiol2025https://conductscience.org/library/papers/39911073PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
INS3630PubTator's text mininghttps://conductscience.org/library/genes/3630

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/38947237

GET https://conductscience.org/api/papers/v1/38947237/references?page=2